# DUART (NCT02891161)

> Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

No report yet. It can be ordered.

- Drugs tested: durvalumab plus radiation therapy
- Indication: localized urothelial cancer of bladder

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02891161
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Monika Joshi, MD
- Conditions: Urothelial Cancer
- Interventions: durvalumab; Radiation Therapy
- Enrollment: 26
- Primary outcome: Phase Ib: Safety Assessment - Evaluation of DLT (Dose Limiting Toxicity) Rate
- Primary outcome: All Phases: Progression Free Survival Rate at 1 Year
- Primary outcome: Phase II: Disease Control Rate to Concurrent durvaRT Followed by Durvalumab

## Indexed commentary on DUART so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 29
- YouTube: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=duart-nct02891161

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02891161", "email": "<work email>"}; the inbox owner confirms by the emailed link.